Chan Phillip P. 4
4 · Cytosorbents Corp · Filed Jun 15, 2026
Research Summary
AI-generated summary of this filing
Cytosorbents (CTSO) CEO Phillip Chan Buys 261,469 Shares
What Happened Phillip P. Chan, CEO of Cytosorbents Corporation (CTSO), made two open-market purchases totaling 261,469 shares. On 2026-06-12 he purchased 251,136 shares at a weighted-average price of $0.40 for about $100,454; on 2026-06-15 he purchased 10,333 shares at a weighted-average price of $0.43 for about $4,443. These were purchases (insider buys), which investors often view as a more informative signal than routine insider sales.
Key Details
- Transaction types: Open-market purchases (reporting code P).
- Dates & prices:
- 2026-06-12: 251,136 shares, weighted avg $0.40 (actual trades ranged $0.3885–$0.40) — $100,454.
- 2026-06-15: 10,333 shares, weighted avg $0.43 (actual trades ranged $0.4307–$0.4388) — $4,443.
- Total shares bought: 261,469; total cash spent: $104,897 (per Form 4).
- Shares owned after transaction (per filing): 1,422,832 shares of Common Stock.
- Notable footnotes:
- Footnotes indicate the reported prices are weighted averages and the filer can provide a per-trade breakdown on request (F1, F4).
- The filing discloses multiple outstanding RSUs that may convert to shares upon certain events: 10,300 (3/15/2018), 18,700 (2/24/2017), 57,000 (6/7/2016), 130,000 (4/8/2015) — vesting on a Change in Control (F2), plus 105,600 RSUs granted 8/8/2025 with time-based vesting (F3).
- Filing timeliness: Form 4 was filed on 2026-06-15 for transactions on 2026-06-12 and 2026-06-15; no late filing was indicated.
Context These purchases were open-market buys (not option exercises or gifts), so the CEO directly increased his equity stake. The filing provides both weighted-average prices and the ranges of execution prices; it does not state any trading plan (e.g., 10b5-1). Investors should treat insider purchases as one data point and consider company fundamentals and broader market context before drawing conclusions.
Insider Transaction Report
- Purchase
Common Stock
[F1][F2][F3]2026-06-12$0.40/sh+251,136$100,454→ 1,734,099 total - Purchase
Common Stock
[F4][F2][F3]2026-06-15$0.43/sh+10,333$4,443→ 1,744,432 total
Footnotes (4)
- [F1]The transaction reported on this Form 4 reflects an open market purchase made by the Reporting Person. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.3885 to $0.40, inclusive. The Reporting Person undertakes to provide to CytoSorbents Corporation (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (4) to this Form 4.
- [F2]Includes: (i) the following restricted stock units ("RSUs") that will be settled into shares of Common Stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan (the "Plan"): (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015;
- [F3](continued from footnote 2) (iii) 105,600 RSUs granted on August 8, 2025, which shall vest in equal parts at the first and second year anniversaries of the date of grant, subject to the Reporting Person's continued service as of the applicable vesting date, and (iv) 1,422,832 shares of Common Stock owned by the Reporting Person.
- [F4]The transaction reported on this Form 4 reflects an open market purchase made by the reporting person. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4307 to $0.4388, inclusive.